Utreglutide is a synthetic peptide that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which are primarily used in the management of type 2 diabetes. This compound is designed to enhance insulin secretion in response to elevated blood glucose levels, thereby aiding in glycemic control. Utreglutide exhibits a prolonged half-life due to its resistance to enzymatic degradation, allowing for less frequent dosing compared to earlier GLP-1 analogs. Its mechanism of action involves binding to GLP-1 receptors, leading to increased insulin release, decreased glucagon secretion, and slowed gastric emptying. Additionally, it may promote weight loss, a beneficial effect for many patients with type 2 diabetes. The safety profile of utreglutide is generally favorable, with common side effects including gastrointestinal disturbances. As with other GLP-1 receptor agonists, careful monitoring is essential to manage potential adverse effects and ensure optimal therapeutic outcomes. Overall, utreglutide represents a promising option in the evolving landscape of diabetes treatment.

Utreglutide

2460862-12-6: Utreglutide is a synthetic peptide that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which are primarily used in the management of type 2 diabetes. This compound is designed to enhance insulin secretion in response to elevated blood glucose levels, thereby aiding in glycemic control. Utreglutide exhibits a prolonged half-life due to its resistance to enzymatic degradation, allowing for less frequent dosing compared to earlier GLP-1 analogs. Its mechanism of action involves binding to GLP-1 receptors, leading to increased insulin release, decreased glucagon secretion, and slowed gastric emptying. Additionally, it may promote weight loss, a beneficial effect for many patients with type 2 diabetes. The safety profile of utreglutide is generally favorable, with common side effects including gastrointestinal disturbances. As with other GLP-1 receptor agonists, careful monitoring is essential to manage potential adverse effects and ensure optimal therapeutic outcomes. Overall, utreglutide represents a promising option in the evolving landscape of diabetes treatment.

<p>Utreglutide is a potent glucagon-like peptide 1 (GLP-1) receptor agonit [1] .</p>

CAS 2460862-12-6

Utreglutide

Utreglutide

Ref: TM-T76237